Leerink bullish on BioMarin following Inozyme deal, expects additional BD

finance.yahoo.com/news/leerink-bullish-biomarin-following-inozyme-173034685.html

In This Article:
Leerink analyst Joseph Schwartz notes BioMarin (BMRN) believes INZ-701 could be a $400M-$600M opportunity at peak, making it a nice addition to the company’s ERT portfolio; this is likely the first business development deal in 2025. Before market open on Friday, BioMarin…

This story appeared on finance.yahoo.com, 2025-05-17 17:30:34.
The Entire Business World on a Single Page. Free to Use →